Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 11, 2020 at 08:07 pm
Share
Genovate Biotechnology Co., Ltd. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was TWD 124.033 million compared to TWD 114.296 million a year ago. Operating income was TWD 15.166 million compared to TWD 11.789 million a year ago. Net income was TWD 14.089 million compared to TWD 11.093 million a year ago. Basic earnings per share was TWD 0.14 compared to TWD 0.11 a year ago. For the half year, sales was TWD 259.868 million compared to TWD 249.652 million a year ago. Operating income was TWD 34.468 million compared to TWD 38.053 million a year ago. Net income was TWD 32.668 million compared to TWD 34.615 million a year ago. Basic earnings per share was TWD 0.32 compared to TWD 0.33 a year ago. Diluted earnings per share was TWD 0.31 compared to TWD 0.33 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 
